News Releases

Search

Year

December 4, 2020

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares

Total gross proceeds from the offering to Cogent are approximately $115.0 million CAMBRIDGE, Mass. , Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences , Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced

December 1, 2020

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

CAMBRIDGE, Mass. , Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 10,256,411 shares of its common stock,

November 30, 2020

Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock

CAMBRIDGE, Mass. , Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $60,000,000 of shares of its common

November 30, 2020

Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer

Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice President of Supply Chain and Manufacturing CAMBRIDGE, Mass. , Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company

November 20, 2020

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference

CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will participate in a virtual

November 18, 2020

Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020

Majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and 20% ORR, including a complete response, in a heavily pre-treated GIST population; 27% of patients remain on therapy out 27-34 months Combination showed no dose limiting toxicities

November 12, 2020

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference

CAMBRIDGE, Mass. , Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present a corporate

November 9, 2020

Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

Andrew Robbins appointed President, CEO and Director Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients selected for oral presentation at Connective Tissue Oncology Society (CTOS) 2020 meeting Ended quarter with $129.4 million in cash, including proceeds from $104.4M Series

November 5, 2020

Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 5, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will virtually present a

October 26, 2020

Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer

Seasoned executive with deep experience developing precision medicines for genetically defined diseases, most recently as COO of Array Biopharma CAMBRIDGE, Mass. , Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences , Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.